Producer
Sanofi Pasteur
Largest seasonal flu vaccine maker (~35%); egg-based Fluzone and recombinant Flublok; FDA-approved H5N1 pandemic vaccine.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Sanofi Pasteur supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Sanofi Pasteur makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Seasonal influenza vaccines
Pandemic / biodefense
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Chokepoint2025
Most of the world's flu vaccine — including Sanofi's Fluzone, from the largest flu-vaccine maker (~35% share) — is still grown the way it has been for ~80 years: by injecting the virus into fertilized chicken eggs and harvesting it days later. That ties global flu-shot supply to a dedicated, months-ahead stream of specially produced eggs and healthy flocks: the U.S. alone would need hens laying ~900,000 eggs a day for nine months to make enough H5N1 vaccine. And it creates a dangerous circular dependency — a severe bird-flu (H5N1) pandemic is lethal to egg-laying poultry, so the outbreak could kill the very chickens needed to manufacture the vaccine against it. A humble fertilized egg is thus a strategic biodefense input, which is why governments fund standby egg contracts and egg-free methods (Sanofi's recombinant Flublok). [verify: Sanofi largest flu maker, egg-based Fluzone, H5N1 circularity established]
CBS News ↗Did you know2024
Sanofi Pasteur's seasonal flu business doubles as national biodefense. The same lines that churn out annual flu shots are the surge capacity governments count on in a pandemic — which is why Sanofi held the first FDA-licensed H5N1 (bird flu) vaccine in 2007 and why agencies like the U.S. BARDA stockpile pandemic-strain doses. A routine consumer medical product (your yearly flu shot) and a strategic pandemic countermeasure are made on the same equipment by the same firm. So sustaining a commercial seasonal-vaccine market is, in effect, how nations keep pandemic-vaccine capacity warm — and why flu-vaccine manufacturing is treated as critical infrastructure, not just a healthcare product. [verify: Sanofi first FDA-licensed H5N1 vaccine 2007, national stockpile confirmed]
Scientific American ↗